Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain
- PMID: 34370562
- DOI: 10.1080/14740338.2021.1965989
Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain
Abstract
Introduction: Opioids for managing postoperative pain are associated with side effects including opioid-induced respiratory depression (OIRD) and gastrointestinal complications. Opioids induce analgesia via G-protein signaling, while adverse effects are mediated by the β-arrestin pathway. Oliceridine is a biased ligand that preferentially activates G-protein signaling over β-arrestin, theoretically reducing adverse effects. Oliceridine has been approved by the Food and Drug Administration to treat acute pain severe enough to require intravenous opioid analgesics.
Areas covered: Preclinical and clinical trials demonstrate the analgesic efficacy of oliceridine. Available evidence suggests that oliceridine may have a lower risk of OIRD and gastrointestinal complications compared to conventional opioids.
Expert opinion: The analgesic efficacy of oliceridine has been evaluated in several clinical trials. However, safety data were obtained from an open-label observational study and studies assessing adverse effects as secondary outcomes, as post-hoc analyses, or from retrospective studies. These may be affected by gaps in detecting adverse events, heterogeneity in the original studies, and the limitations of retrospective studies. Prospective trials examining the safety of oliceridine versus conventional opioids are needed. Studies are also needed to assess the safety and efficacy of oliceridine in obstetric and pediatric populations, and in the context of multimodal analgesia and Enhanced Recovery after Surgery protocols.
Keywords: Biased ligand; TRV130; mu-opioid receptor; opioid agonist.
Similar articles
-
Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.Pain Res Manag. 2020 Oct 24;2020:7492865. doi: 10.1155/2020/7492865. eCollection 2020. Pain Res Manag. 2020. PMID: 33163127 Free PMC article.
-
Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain.Clin Drug Investig. 2020 Aug;40(8):755-764. doi: 10.1007/s40261-020-00936-0. Clin Drug Investig. 2020. PMID: 32583295 Free PMC article.
-
APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.Pain Pract. 2019 Sep;19(7):715-731. doi: 10.1111/papr.12801. Epub 2019 Jun 24. Pain Pract. 2019. PMID: 31162798 Free PMC article. Clinical Trial.
-
Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain - A Review of Current Evidence.J Pain Res. 2021 Apr 14;14:969-979. doi: 10.2147/JPR.S278279. eCollection 2021. J Pain Res. 2021. PMID: 33889018 Free PMC article. Review.
-
Oliceridine: First Approval.Drugs. 2020 Nov;80(16):1739-1744. doi: 10.1007/s40265-020-01414-9. Drugs. 2020. PMID: 33025536 Review.
Cited by
-
Global Trends in Oliceridine (TRV130) Research from 2013 to 2024: A Bibliometrics and Knowledge Graph Analysis.Drug Des Devel Ther. 2024 Oct 21;18:4681-4692. doi: 10.2147/DDDT.S475205. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 39464167 Free PMC article.
-
Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids.Acta Pharm Sin B. 2023 Jan;13(1):82-99. doi: 10.1016/j.apsb.2022.09.018. Epub 2022 Sep 25. Acta Pharm Sin B. 2023. PMID: 36815042 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
